EP2552462 - CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 21.10.2016 Database last updated on 09.09.2024 | Most recent event Tooltip | 12.10.2018 | Lapse of the patent in a contracting state New state(s): AL | published on 14.11.2018 [2018/46] | Applicant(s) | For all designated states Rosalind Franklin University of Medicine and Science 3333 Green Bay Road North Chicago, IL 60064 / US | [2013/06] | Inventor(s) | 01 /
RISER, Bruce 313 54th Street Kenosha Wisconsin 53140 / US | [2013/06] | Representative(s) | AWA Sweden AB Box 5117 200 71 Malmö / SE | [N/P] |
Former [2015/51] | Jakobsson, Jeanette Helene Awapatent AB P.O. Box 5117 200 71 Malmö / SE | ||
Former [2013/06] | Jakobsson, Jeanette Helene Awapatent AB Matrosgatan 1 P.O. Box 5117 20071 Malmö / SE | Application number, filing date | 11763563.1 | 04.04.2011 | [2015/51] | WO2011US31121 | Priority number, date | US20100341694P | 02.04.2010 Original published format: US 341694 P | [2013/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2011123858 | Date: | 06.10.2011 | Language: | EN | [2011/40] | Type: | A2 Application without search report | No.: | EP2552462 | Date: | 06.02.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.10.2011 takes the place of the publication of the European patent application. | [2013/06] | Type: | B1 Patent specification | No.: | EP2552462 | Date: | 16.12.2015 | Language: | EN | [2015/51] | Search report(s) | International search report - published on: | US | 24.11.2011 | (Supplementary) European search report - dispatched on: | EP | 14.11.2013 | Classification | IPC: | A61K35/12, A61K38/10, C07K7/08, A61P9/10, A61P35/00, A61P19/08, A61P43/00, A61P9/00, A61N1/30 | [2013/06] | CPC: |
A61K38/10 (EP,US);
A61K38/08 (EP,US);
A61P1/02 (EP);
A61P1/16 (EP);
A61P11/00 (EP);
A61P13/12 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P19/00 (EP);
A61P19/02 (EP);
A61P19/08 (EP);
A61P25/00 (EP);
A61P27/02 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/06] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | CCN3-PEPTIDE UND ANALOGE DAVON ZUR THERAPEUTISCHEN VERWENDUNG | [2013/06] | English: | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | [2013/06] | French: | PEPTIDES CCN3 À VISÉE THÉRAPEUTIQUE ET LEURS ANALOGUES | [2013/06] | Entry into regional phase | 05.10.2012 | National basic fee paid | 05.10.2012 | Search fee paid | 05.10.2012 | Designation fee(s) paid | 05.10.2012 | Examination fee paid | Examination procedure | 05.10.2012 | Examination requested [2013/06] | 28.03.2014 | Amendment by applicant (claims and/or description) | 02.07.2015 | Communication of intention to grant the patent | 22.10.2015 | Fee for grant paid | 22.10.2015 | Fee for publishing/printing paid | 22.10.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 02.07.2015 | Opposition(s) | 19.09.2016 | No opposition filed within time limit [2016/47] | Fees paid | Renewal fee | 29.04.2013 | Renewal fee patent year 03 | 25.03.2014 | Renewal fee patent year 04 | 10.04.2015 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 04.04.2011 | AL | 16.12.2015 | AT | 16.12.2015 | BG | 16.12.2015 | CY | 16.12.2015 | CZ | 16.12.2015 | EE | 16.12.2015 | FI | 16.12.2015 | HR | 16.12.2015 | LT | 16.12.2015 | LV | 16.12.2015 | MC | 16.12.2015 | MK | 16.12.2015 | PL | 16.12.2015 | RO | 16.12.2015 | RS | 16.12.2015 | SI | 16.12.2015 | SK | 16.12.2015 | SM | 16.12.2015 | TR | 16.12.2015 | NO | 16.03.2016 | GR | 17.03.2016 | IE | 04.04.2016 | LU | 04.04.2016 | IS | 16.04.2016 | PT | 18.04.2016 | MT | 30.04.2016 | [2018/46] |
Former [2018/38] | HU | 04.04.2011 | |
AT | 16.12.2015 | ||
BG | 16.12.2015 | ||
CY | 16.12.2015 | ||
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
MC | 16.12.2015 | ||
MK | 16.12.2015 | ||
PL | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SI | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
TR | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
IE | 04.04.2016 | ||
LU | 04.04.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
MT | 30.04.2016 | ||
Former [2018/31] | HU | 04.04.2011 | |
AT | 16.12.2015 | ||
CY | 16.12.2015 | ||
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
MC | 16.12.2015 | ||
MK | 16.12.2015 | ||
PL | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SI | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
TR | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
IE | 04.04.2016 | ||
LU | 04.04.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
MT | 30.04.2016 | ||
Former [2018/29] | HU | 04.04.2011 | |
AT | 16.12.2015 | ||
CY | 16.12.2015 | ||
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
MC | 16.12.2015 | ||
MK | 16.12.2015 | ||
PL | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SI | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
TR | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
IE | 04.04.2016 | ||
LU | 04.04.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
Former [2018/28] | HU | 04.04.2011 | |
AT | 16.12.2015 | ||
CY | 16.12.2015 | ||
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
MC | 16.12.2015 | ||
MK | 16.12.2015 | ||
PL | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SI | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
IE | 04.04.2016 | ||
LU | 04.04.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
Former [2017/38] | AT | 16.12.2015 | |
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
PL | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SI | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
IE | 04.04.2016 | ||
LU | 04.04.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
Former [2017/16] | AT | 16.12.2015 | |
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
PL | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SI | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
LU | 04.04.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
Former [2017/04] | AT | 16.12.2015 | |
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
PL | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
LU | 04.04.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
Former [2016/49] | AT | 16.12.2015 | |
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
PL | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
Former [2016/38] | AT | 16.12.2015 | |
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SK | 16.12.2015 | ||
SM | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
IS | 16.04.2016 | ||
PT | 18.04.2016 | ||
Former [2016/36] | AT | 16.12.2015 | |
CZ | 16.12.2015 | ||
EE | 16.12.2015 | ||
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
RO | 16.12.2015 | ||
RS | 16.12.2015 | ||
SK | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
Former [2016/34] | CZ | 16.12.2015 | |
FI | 16.12.2015 | ||
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
RS | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
Former [2016/25] | FI | 16.12.2015 | |
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
LV | 16.12.2015 | ||
RS | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
Former [2016/24] | FI | 16.12.2015 | |
HR | 16.12.2015 | ||
LT | 16.12.2015 | ||
RS | 16.12.2015 | ||
NO | 16.03.2016 | ||
GR | 17.03.2016 | ||
Former [2016/23] | HR | 16.12.2015 | |
LT | 16.12.2015 | ||
RS | 16.12.2015 | ||
NO | 16.03.2016 | ||
Former [2016/21] | LT | 16.12.2015 | |
NO | 16.03.2016 | ||
Former [2016/20] | LT | 16.12.2015 | Documents cited: | Search | [Y]FR2858234 (CENTRE NAT RECH SCIENT [FR], et al) [Y] 1-12* page 2, line 9 - page 3, line 25 *; | [Y]WO2008035024 (UNIV BELFAST [GB], et al) [Y] 1-12 * page 4, line 11 - page 5, line 6 * * page 8, line 5 - page 13, line 30 * | International search | [Y]WO2006036962 (LAU LESTER F [US]); | [X]US2006178332 (RISER BRUCE L [US]); | [Y]US2010004169 (IRVINE ALEXANDRA ELIZABETH [GB], et al); | [A] - GUPTA ET AL., "NOV (CCN3) functions as a regulator of human hematopoietic stern or progenitor cells.", SCIENCE, (2007), vol. 316, no. 5824, pages 590 - 593, XP008166533 DOI: http://dx.doi.org/10.1126/science.1136031 | [A] - UNIPROT, (20100302), Database accession no. P48745, XP008166529 | by applicant | US7780949 | - PERBAL B., "NOV and the CCN family of genes: structural and functional issues", MOLECULAR PATHOLOGY, (2001), vol. 54, doi:doi:10.1136/mp.54.2.57, pages 57 - 79, XP008010743 DOI: http://dx.doi.org/10.1136/mp.54.2.57 | - BRIGSTOCK D. R., "Regulation of angiogenesis and endothelial cell function by connective tissue growth factor", FEBS LETTERS, (2003), vol. 327, pages 125 - 130 | - MASON, R., "Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?", J. CELL COMMUN. SIGNAL, (2009), vol. 3, pages 95 - 104 | - DEAN R.G.; BALDING L.; CANDIDO R.; BUMS W.C.; CAO Z.; TWIGG S.M.; BURRELL L,M., "Connective tissue growth factor and cardiac fibrosis after myocardial infarction", JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, (2005), vol. 53, no. 10, pages 1245 - 56 | - SHI-WEN X.; PENNINGTON D.; HOLMES A.; LEASK A.; BRADHAM D.; BEAUCHAMP J.R.; FONSECA C.; DU BOIS R.M.; MARTIN G.R.; BLACK C.M., "Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis", EXPERIMENTAL CELL RESEARCH, (2000), vol. 259, no. 1, pages 213 - 24 | - OZAKI S.; SATO Y.; YASOSHIMA M.; HARADA K.; NAKANUMA Y., "Diffuse expression of heparan sulfate proteoglycan and connective tissue growth factor in fibrous septa with many mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis", LIVER INTERNATIONAL., (2005), vol. 25, no. 4, pages 817 - 28 | - SAKAMOTO N.; SUGIMURA K.; KAWASHIMA H.; TSUCHIDA K.; TAKEMOTO Y.; NAGANUMA T.; TATSUMI S.; NAKATANI T., "Influence of glucose and inflammatory cytokines on TGF-betal and CTGF mRNA expressions in human peritoneal mesothelial cells", INTERNATIONAL JOURNAL OFMOLECULAR MEDICINE, (2005), vol. 15, no. 6, pages 907 - 11 | - ZARRINKALAM K.H.; STANLEY J.M.; GRAY J.; OLIVER N.; FAULL R.J., "Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients", KIDNEY INTERNATIONAL., (2003), vol. 64, no. 1, pages 331 - 8 | - BRADHAM DM ET AL., "Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to SCR-induced immediate early gene product CEF-10", JOURNAL OF CELL BIOLOGY, (1991), vol. 114, pages 1285 - 1294 | - RISER, BL ET AL., "CCN2 (CTGF): as a possible predictor of diabetic nephropathy: Preliminary report", KIDNEV INTERNATIONAL, (2003), vol. 64, doi:doi:10.1046/j.1523-1755.2003.00130.x, pages 451 - 458, XP002324650 DOI: http://dx.doi.org/10.1046/j.1523-1755.2003.00130.x | - FK TAM ET AL., "Urinary monocyte chemoattractant protein- (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy", CYTOKINE, (2009), vol. 47 1, doi:doi:10.1016/j.cyto.2009.04.001, pages 37 - 42, XP026211841 DOI: http://dx.doi.org/10.1016/j.cyto.2009.04.001 | - CANCER RESEARCH, (2000), vol. 60, pages 5602 - 5607 | - TSAI ET AL., "Expression and regulation of Cyr61 in human breast cancer cell lines", ONCOGENE, (2000), vol. 21, pages 964 - 974 | - SAMPATH ET AL., "Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17 beta-estradiol and overexpression in human breast cancer", ENDOCRINOLOGY, (2001), vol. 142, pages 2540 - 2548 | - SAMPATH ET AL., "Aberrant expression of Cyr 61, a member of the CCN family (i.e. CCN1), and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, (2001), vol. 86, pages 1707 - 1715 | - SAMPATH ET AL., "The angiogenic factor Cyr61 is induced by progestin R5020 and is necessary for mammary adenocarcinorma cell growth", ENDOCRINE, (2002), vol. 18, pages 147 - 150 | - XIE ET AL., "Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease", BREAST CANCER, (2001), vol. 276, pages 14187 - 14194, XP002429498 | - XIE ET AL., "Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features", CANCER RESEARCH, (2002), vol. 61, pages 8917 - 8923, XP009071488 | - RAGEH ET AL., "Steroidal regulation of connective tissue growth factor (CCN2; CTGF) synthesis in the mouse uterus.", MOLECULAR PATHOLOGY, (2001), vol. 56, pages 80 - 85 | - CHEON ET AL., "A genomic approach to identify novel progesterone receptor regulated pathways in the uterus during implantation", MOLECULAR ENDOCRINOLOGY, (2002), vol. 16, pages 2853 - 2871 | - WANDJI ET AL., "Messenger ribonucleic acids for MAC25 and connective tissue growth factor (CTGF) are inversely regulated during folliculogenesis and early luteogenesis", KIDNEY INTERNATIONAL, (2000), vol. 60, pages 96 - 105 | - SLEE ET AL., "Differentiation-dependent expression of connective tissue growth factor and lysyl oxidase messenger ribonucleic acids in rat granulose cells", ENDOCRINOLOGY, (2001), vol. 142, pages 1082 - 1089 | - HARLOW; HILLAR, "Connective tissue growth factor in the ovarian paracrine system", MOLECULAR AND CELLULAR ENDOCRINOLOGY, (2002), vol. 187, pages 23 - 27 | - HARLOW ET AL., "FSH and TGF-beta superfamily members regulate granulose cell connective tissue growth factor gene expression in vitro and in vivo", ENDOCRINOLOGY, (2002), vol. 143, pages 3316 - 3325 | - LIU ET AL., "Gonodotrophins inhibit the expression of insulin-like growth binding protein-related protein-2 mRNA in cultured human granulose-luteal cells", MOLECULAR HUMAN REPRODUCTION, (2002), vol. 8, pages 136 - 141 | - PERBAL B., J CLIN. PATHOL: MOL PATHOL., (2001), vol. 54, pages 57 - 79 | - PERBAL B., J CLIN. PATHOL: MOL PATHOL, (2001), vol. 54, pages 57 - 79 | - KYURKCHIEV S. ET AL., "Potential cellular conformations of the CCN3 (NOV) protein", CELLULAR COMMUNICATION AND SIGNALING, (2004), vol. 2, pages 9 - 18 | - LI, C. L. ET AL., "A role for CCN3 (NOV) in calcium signaling", JOURNAL OF CLINICAL PATHOLOGY: MOLECULAR PATHOLOGY, (2002), vol. 55, pages 250 - 261 | - RISER ET AL., "CCN3 is a negative regulator ofCCN2 and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease", AMERICAN J PATHOLOGY, (2009), vol. 174, no. 5 | - MCCALLUM, L ET AL., "CCN3: a key growth regulator in Chronic Myeloid Leukaemia", J CELL COMMUN SIGNAL., (200906), vol. 3, no. 2, pages 115 - 124 |